Characterization of the Evolution of the Pharmaceutical Regulatory Environment

References

1. 1.↵
   1. Hartmann M.,
   2. Hartmann-Vareilles F.

   Recent developments in European pharmaceutical law 2004: a legal point of view. Drug Information J. 2005, 39 (2),193–207.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
2. 2.↵
   1. Tancer R. S.,
   2. Mosseri-Marlio C.

   Evolution of pharmaceutical regulations and their consequences in the European Union and the United States. Thunderbird International Business 2002, 44 (2), 263–281.

   OpenUrlGoogle Scholar
3. 3.↵
   1. Li Bassi L.,
   2. Bertele V.,
   3. Garattini S.

   European regulatory policies on medicines and public health needs. Eur. J. Public Health 2003, 13 (3), 246–251.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
4. 4.↵
   1. Borchers A. T.,
   2. Hagie F.,
   3. Keen C. L.,
   4. Gershwin M. E.

   The history and contemporary challenges of the US Food and Drug Administration. Clinical Therapeutics 2007, 29 (1), 1–16.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
5. 5.↵
   US Food and Drug Administration (FDA). Regulatory Information: Legislation. Department of Health and Human Services: Rockville, MD, 2007; http://www.fda.gov/RegulatoryInformation/Legislation/default.htm. Accessed October 30, 2011.

   Google Scholar
6. 6.↵
   US Supreme Court. United States v. Bacto-Unidisk, 394 U.S. 784, 1969; http://supreme.justia.com/cases/federal/us/394/784/case.html. Accessed October 30, 2011.

   Google Scholar
7. 7.↵
   US Congress. Food, Drug, and Cosmetic Act, SEC. 505. (21 USC §355) New Drugs. FDCA Amendment; Accessed 30 October 2011.

   Google Scholar
8. 8.↵
   United States Government Accountability Office. Improvement Needed in FDA's Post-market Decision-making and Oversight Process. Report to Congressional Requesters, Washington, DC, 2006.

   Google Scholar
9. 9.↵
   US FDA. FDA Strategic Action Plan: Charting Our Course for the Future; Department of Health and Human Services: Rockville, MD, 2007; http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/StrategicActionPlan/UCM061415.pdf. Accessed on October 30, 2011.

   Google Scholar
10. 10.↵
    1. Platt R.,
    2. Wilson M.,
    3. Chan K. A.,
    4. Benner J. S.,
    5. Marchibroda J.,
    6. McClellan M.

    The new Sentinel Network—improving the evidence of medical-product safety. N. Engl. J. Med. 2009, 361 (7), 645–647.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
11. 11.↵
    1. Psaty B. M.,
    2. Burke S. P.

    Protecting the health of the public—Institute of Medicine recommendations on drug safety. N. Engl. J. Med. 2006, 355 (17), 1753–1755.

    OpenUrlCrossRefPubMedGoogle Scholar
12. 12.↵
    Pharmaceutical Manufacturers of America. PhRMA Statement on Health Care Reform Coalition; Pharmaceutical Manufacturers of America: Washington, DC, 2009; http://www.phrma.org/media/releases/phrma-statement-healthcare-reform-coalition. Accessed October 30, 2011.

    Google Scholar
13. 13.↵
    Institute for Crises Management. News coverage of business crisis during 2008. Annual ICM Crisis Report, Louisville, Kentucky: 2009, 18 (1).

    Google Scholar
14. 14.↵
    1. Funning S.,
    2. Grahnen A.,
    3. Eriksson K.,
    4. Kettis-Linbald A.

    Quality assurance within the scope of good clinical practice (GCP)—What is the cost of GCP-related activities? A survey within the Swedish Association of the Pharmaceutical Industry (LIF)'s members. Quality Assurance J. 2009, 12 (1), 3–7.

    OpenUrlGoogle Scholar
15. 15.↵
    The European Medicines Agency (EMA). Road Map to 2010: Preparing the Ground for the Future; EMA: London, 2005. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000164.jsp&mid=WC0b01ac05800293fc. Accessed October 30, 2011.

    Google Scholar
16. 16.↵
    1. Bass S.,
    2. Klasmeier C.

    US Food and Drug Administration and European Medicines Agency Enter into New Good Clinical Practices Collaboration; Sidley Austin, LLP: New York, 2009.

    Google Scholar
17. 17.↵
    1. Sudhop T.,
    2. Brandt S.,
    3. Kiesinger-Allee K. G.,
    4. Keitel S.

    Pharmaceutical innovation: possibilities and limits of personalized medicine. Bundesgesundheitsbl–Gesundheitsforsch–Gesundheitsschutz 2008, 51, 675–688.

    OpenUrlGoogle Scholar
18. 18.↵
    1. Abraham J.,
    2. Lewis G.

    Harmonising and competing for medicines regulation: How healthy are the European Union's systems of drug approval? Social Science and Medicine 1999, 48 (11), 1655–1667.

    OpenUrlGoogle Scholar
19. 19.↵
    1. Epstein J.,
    2. Seitz R.,
    3. Dhingra N.,
    4. Ganz P. R.,
    5. Gharehbaghian A.,
    6. Spindel R.,
    7. Teo D.,
    8. Reddy R.

    Role of regulatory agencies. Biologicals. 2009, 37 (2), 94–102.

    OpenUrlPubMedGoogle Scholar
20. 20.↵
    1. Schwartzman D.

    Innovation in the Pharmaceutical Industry; Johns Hopkins University Press: Baltimore, MD, 1976.

    Google Scholar
21. 21.↵
    World Health Organization. 12th International Conference of Drug Regulatory Authorities Recommendations, 2006.

    Google Scholar
22. 22.↵
    1. Carney S.

    Interview: Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development. Drug Discov. Today 2005, 10 (21), 1411–1414.

    OpenUrlPubMedGoogle Scholar
23. 23.↵
    1. Woodcock J.

    The Role of Biotechnology and Bioinformatics in FDA's Critical Path Initiative. FDA: Rockville, MD, 2007; http://www.slidefinder.net/t/the_role_biotechnology_bioinformatics_fda/3066274. Accessed October 30, 2011.

    Google Scholar
24. 24.↵
    1. Woodcock J.,
    2. Woosley R.

    The FDA Critical Path Initiative and its influence on new drug development. Ann. Rev. Med. 2008, 59, 1–12.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
25. 25.↵
    US FDA. Critical Path Opportunities Initiative; 2007; http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077248.htm. Accessed October 30, 2011.

    Google Scholar
26. 26.↵
    EMEA/SHMP Think-Tank Group. Final Report—Innovative Drug Development Approaches; Medicines Control Agency, 2007; http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500004913.pdf. Accessed October 30, 2011.

    Google Scholar
27. 27.↵
    US FDA. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products; 2004. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm. Accessed October 30, 2011.

    Google Scholar
28. 28.↵
    1. Merrill R. A.

    Modernizing the FDA: an incremental revolution. Health Affairs 1999, 18 (2), 96–111.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
29. 29.↵
    1. Worthen D. B.

    Pharmaceutical legislation: an historical perspective. International Journal of Pharmaceutical Compounding 2006, 10 (1), 20–28.

    OpenUrlGoogle Scholar
30. 30.↵
    1. Abraham J.,
    2. Davis C.

    Comparative analysis of drug safety withdrawals in the UK and the US (1971–1992): implications for current regulatory thinking and policy. Social Science and Medicine 2005, 61 (5), 881–892.

    OpenUrlGoogle Scholar
31. 31.↵
    1. Shafiei N.,
    2. Ford J. L.,
    3. Morecroft C. W.,
    4. Lisboa P. J.,
    5. Taylor M. J.,
    6. Mouzughi Y.

    Transformation in the pharmaceutical industry—a systematic review of the literature. PDA J. Pharm. Sci. Technol. 2013; 67:105–122.

    OpenUrlAbstract/FREE Full TextGoogle Scholar